ADA and rheumatoid arthritis: Firstly, an immune-module composed of 7 differentially expressed markers (DEMs) discriminating ADA+ vs. ADA− RA patients, was identified in B cell subsets in a cross-sectional cohort of adalimumab-treated RA patients (UK-resident).